Catalent, Inc. (NYSE:CTLT – Get Rating)'s stock price was down 4.1% on Tuesday after Barclays lowered their price target on the stock from $62.00 to $58.00. Barclays currently has an overweight rating on the stock. Catalent traded as low as $50.36 and last traded at $50.44. Approximately 154,255 shares were traded during trading, a decline of 94% from the average daily volume of 2,555,757 shares. The stock had previously closed at $52.59.

Other equities research analysts have also recently issued research reports about the company. Morgan Stanley dropped their price objective on Catalent from $120.00 to $81.00 and set an "overweight" rating on the stock in a research note on Thursday, November 3rd. Bank of America cut Catalent from a "buy" rating to a "neutral" rating and lowered their price objective for the stock from $125.00 to $60.00 in a research report on Wednesday, November 2nd. Argus lowered Catalent from a "buy" rating to a "hold" rating in a report on Monday, November 7th. Royal Bank of Canada reduced their target price on Catalent from $125.00 to $73.00 and set an "outperform" rating on the stock in a report on Wednesday, November 2nd. Finally, TheStreet lowered Catalent from a "b-" rating to a "c+" rating in a research note on Friday, October 28th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $92.40.

Insider Buying and Selling at Catalent

In related news, SVP Michael J. Grippo sold 2,451 shares of the business's stock in a transaction on Monday, October 31st. The stock was sold at an average price of $65.83, for a total transaction of $161,349.33. Following the sale, the senior vice president now directly owns 17,792 shares in the company, valued at approximately $1,171,247.36. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, SVP Michael J. Grippo sold 2,451 shares of the business's stock in a transaction dated Monday, October 31st. The stock was sold at an average price of $65.83, for a total transaction of $161,349.33. Following the completion of the transaction, the senior vice president now directly owns 17,792 shares in the company, valued at $1,171,247.36. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Manja Boerman sold 780 shares of the company's stock in a transaction dated Monday, December 5th. The stock was sold at an average price of $51.70, for a total value of $40,326.00. Following the completion of the transaction, the insider now owns 15,860 shares of the company's stock, valued at $819,962. The disclosure for this sale can be found here. Corporate insiders own 0.58% of the company's stock.

Institutional Investors Weigh In On Catalent

Catalent Price Performance

The business has a 50-day simple moving average of $46.22 and a 200 day simple moving average of $72.04. The firm has a market cap of $8.92 billion, a P/E ratio of 21.18, a price-to-earnings-growth ratio of 3.41 and a beta of 1.24. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.08 and a current ratio of 2.86.

Catalent (NYSE:CTLT – Get Rating) last released its quarterly earnings results on Tuesday, November 1st. The company reported $0.25 EPS for the quarter, missing analysts' consensus estimates of $0.49 by ($0.24). Catalent had a net margin of 8.83% and a return on equity of 12.55%. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. On average, analysts anticipate that Catalent, Inc. will post 2.93 earnings per share for the current fiscal year.

About Catalent

(Get Rating)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Further Reading

• Get a free copy of the StockNews.com research report on Catalent (CTLT)
• High-Yield, Deep-Value Verizon Puts In A Bottom
• Should You Bet Against The Nasdaq 100 With This Inverse ETF?
• Can Coty Stock Emerge in 2023 With Upside
• Insiders Buy Archer Aviation, Is This Stock About To Take Off?
• Intuit Is About To Make a Move, But Which Way?

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.